Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases. The company’s unique technology platform can address a wide range of autoimmune and immunologic diseases. Imotopes™ are modified synthetic peptides, which specifically block improper immune activity. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no effective therapeutic alternative and has the potential to cure patients without impairing their immune defenses. Our vision is to become a leader in the field of active specific immunotherapy and to prevent, stop and potentially cure autoimmune diseases. Headquartered in Liège, Belgium, Imcyse was founded as a spin-off of the Catholic University of Leuven (KULeuven). Imcyse’s Imotope™ technology platform is protected by a robust, international intellectual property portfolio. Our lead Imotope™, IMCY-0098, is in phase 2 clinical testing for early onset type 1 diabetes.
View Top Employees from Imcyse SAWebsite | http://www.imcyse.com |
Revenue | $5 million |
Funding | $39.5 million |
Employees | 56 (56 on RocketReach) |
Founded | 2011 |
Address | Giga B34 Avenue De L'hôpital, Sart Tilman 4000, BE |
Phone | (321) 633-0561 |
Technologies |
JavaScript,
HTML,
PHP
+7 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Medical Testing & Clinical Laboratories, Healthcare, Science and Engineering, Pharmaceuticals, Pharmaceutical, Health Care, Therapeutics |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 54199 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 5419 Companies |
Looking for a particular Imcyse SA employee's phone or email?
The Imcyse SA annual revenue was $5 million in 2024.
Denis Bedoret is the CEO of Imcyse SA.
56 people are employed at Imcyse SA.
The NAICS codes for Imcyse SA are [54199, 54, 541, 5419].
The SIC codes for Imcyse SA are [873, 87].